The malaria vaccine is now saving children's lives outside the lab — and funding, not supply, is the wall

For decades, malaria has killed children faster than almost any other infectious disease in Africa — an estimated 438,000 African children died of it in 2024 alone. The world's first malaria vaccine, RTS,S/AS01E, promised to change that. The open question was whether the protection seen in tightly controlled clinical trials would survive contact with the messy reality of routine immunisation programmes. On 8 May 2026, the World Health Organization said it has its answer: the vaccine is saving children's lives in the real world, and at a scale that broadly matches the trials.

What the new evidence actually shows

The headline finding comes from a large evaluation published in The Lancet, drawing on the pilot implementation programme that introduced RTS,S in Ghana, Kenya and Malawi between 2019 and 2023. Over the four-year period, around 1 in 8 deaths among children eligible for the vaccine was averted in areas where it was given. That is a population-level mortality signal — the kind public-health officials had hoped for but could not assume.

A separate Phase 4 effectiveness study of roughly 45,000 children under five, reported by the University of Minnesota's CIDRAP, put numbers on the protection: a 17% reduction in all-cause mortality, a 58% reduction in severe malaria, a 36% drop in malaria-related hospitalisations and a 30% reduction in any malaria. Crucially, these real-world figures equal or exceed the original trial results — a 58% cut in severe disease is actually stronger than the trial benchmark for that outcome.

Why "matching the trials" is the whole story

Vaccine effectiveness in the field almost always lags efficacy in a trial, because real programmes face missed appointments, cold-chain gaps and variable transmission. As the study authors note, effectiveness "might differ from the efficacy results observed in the controlled environment of clinical trials and will depend on malaria incidence." That the malaria vaccine has held its ground is the reason WHO is confident the impact "is likely to be as high or higher" in the other countries now rolling it out.

How the vaccine works

RTS,S/AS01E targets Plasmodium falciparum, the deadliest malaria parasite, at the stage just after a mosquito bite, before it can establish infection in the liver. Protection depends on completing a four-dose schedule that begins around five months of age and runs through age two. The fourth, booster dose matters: it is what sustains protection through the second year of life, when many malaria deaths occur. WHO notes the four visits also create opportunities to deliver other childhood vaccines — but they are also the programme's main vulnerability, because each added visit is a chance for a child to drop out.

The rollout is scaling fast

Adoption has accelerated sharply. 25 endemic African countries are now offering malaria vaccines through routine immunisation, covering nine of the ten highest-burden countries, and 28.3 million doses were distributed in 2025 — a roughly 169% jump over the prior year. WHO and Gavi report more than 52 million doses delivered since 2023. A second WHO-recommended vaccine, R21/Matrix-M, has widened supply and driven down price.

Country-level data echo the evaluation. Burkina Faso's health ministry reported recorded malaria cases fell from about 10.8 million in 2024 to 7.3 million in 2025 — a 32% decline overall, and a 39% drop among children under five, with under-five mortality falling by more than 40%, according to Gavi. Cameroon documented a 17% reduction in laboratory-confirmed malaria cases between 2024 and 2025. These are ecological figures shaped by bed nets, treatment and rainfall as well as vaccination, so they are not pure vaccine effects — but they point the same direction as the controlled studies.

The caveats — and the funding cliff

The vaccine is a powerful complement to existing tools, not a replacement: it works alongside bed nets, indoor spraying and prompt treatment. Two practical risks remain. The first is fourth-dose uptake — coverage that falls off at the booster erodes the second-year protection that drives much of the mortality benefit. The second is reaching high-coverage in the hardest-to-serve districts.

But WHO is blunt that the binding constraint now is money, not vaccine supply. The agency estimates the two recommended vaccines could prevent up to 500,000 child deaths by 2035 if scaled across moderate- and high-transmission areas — yet the global malaria programme faces a nearly 30% budget shortfall, which WHO and UN News warn could translate into hundreds of thousands of lives not saved by decade's end. Countries need sustained financing not just to buy doses but to deliver them. After years of waiting for a malaria vaccine that works, the risk now is a preventable failure of will.